NBTX — Nanobiotix S.A.

Nasdaq · Health Care · Pharmaceuticals · CIK 1760854 ·
Last close
$36.07
Market Cap
$1.83B
52W High
$57.14
52W Low
$28.40
ADV30
77,267
Next earnings
2026-03-31
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 67,760,000 52,750,000 152,243,000
Jun 2025 45,174,000 28,818,000 114,126,000
Dec 2024 67,418,000 49,737,000 133,121,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-23,961,000
Inventory
Receivables
$7,680,000
ST Investments
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$32,593,000
EBITDA
$-10,489,000
Free Cash Flow
$-7,894,125
Enterprise Value
$1,784,051,328
Total Cash
$52,750,000
Total Debt
$95,319,000
Shares Out
50,785,785
Trailing EPS
$-0.58
Book Value
$-2.03
ROE
ROA
-10.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 29,643,000 -10,818,000 -23,961,000 67,760,000 152,243,000 -33,422,000
Dec 2024 -11,610,000 -68,392,000 -68,132,000 67,418,000 133,121,000 -19,551,000
Dec 2023 30,058,000 -26,778,000 -39,700,000 93,897,000 95,741,000 -12,476,000
Dec 2022 0 -46,703,000 -57,041,000 59,769,000 86,814,000 -37,103,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.08

Peers — same industry

TickerNameMarket CapLastDaily %
ANIP ANI PHARMACEUTICALS INC $1.83B $80.52
VRDN Viridian Therapeutics, Inc.\DE $1.85B $16.71
GLPGF Lakefront Biotherapeutics NV $1.85B $28.08
NUVB Nuvation Bio Inc. $1.85B $5.33
HMDCF HUTCHMED (China) Ltd $1.86B $2.16

News headlines (Yahoo Finance, 1h cache)

Voting Rights and Shares Capital of the Company
2026-06-05 20:15 · Yahoo
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
2026-06-02 20:30 · Yahoo
Nanobiotix Joins the Euronext Tech Leaders Index
2026-06-02 06:30 · Yahoo
Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share Rally
2026-05-30 22:04 · Yahoo
NANOBIOTIX Announces Closing of Global Offering
2026-05-26 20:59 · Yahoo
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
2026-05-22 20:15 · Yahoo
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
2026-05-21 14:57 · Yahoo
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
2026-05-21 13:30 · Yahoo
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Uncertainty Surrounding US-Iran Talks
2026-05-21 13:18 · Yahoo
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
2026-05-21 06:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.